Soluble CTLA-4 and high-risk genetic variants: A new frontier in pancreatic ductal adenocarcinoma (PDAC) biomarkers

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Hassan M.; Elhusseny Y.; Agamy F.E.; Azmy M.M.; Balata M.

Journal: Biochemistry and Biophysics Reports

Publisher: Elsevier B.V.

Publication Date: December 2025

Volume / Issue: Volume 44

Article No.: 102304

ISSN: 24055808

DOI: 10.1016/j.bbrep.2025.102304

Scopus: View on Scopus

Document Type: Article

Access: All Open Access; Gold Open Access; Green Open Access


Authors and Affiliations

Hassan M., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Elhusseny Y., Medical Biochemistry and Molecular Biology, School of Medicine, NewGiza University, Giza, Egypt; Agamy F.E., Faculty of Medicine, Al-Azhar university, Cairo, Egypt; Azmy M.M., Faculty of Biotechnology, Misr University for Science and Technology, Giza, Egypt; Balata M., University Hospital Rostock, Ernst-Heydemann-Straße 6, Rostock, 18057, Germany, University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany


Abstract

CTLA-4 is regarded as the “leader” of immune checkpoint inhibitors, as it suppresses autoreactive T cells at the initial phase of naïve T-cell activation. Its genetic variability may impair its effectiveness in the anti-tumor response. Additionally, the presence of soluble CTLA-4 (sCTLA-4) in the tumor microenvironment suppresses effector T-cell activation, allowing for tumor evasion. Therefore, this study aimed to explore the relationship between CTLA-4 polymorphisms and sCTLA-4 and the risk of pancreatic ductal adenocarcinoma (PDAC) in an Egyptian population. Three single-nucleotide polymorphisms of the CTLA-4 gene (rs231726, rs11571317, and rs13384548) were analyzed, and sCTLA-4 levels were assessed in 125 PDAC patients and 125 healthy controls. The rs231726 TT genotype was associated with a six-fold greater risk of PDAC, advanced disease grades, and elevated carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA). Also, the T-allele increased the likelihood of developing PDAC by four times. Conversely, the CC genotype and C-allele conferred protection against PDAC development. The rs11571317 CC genotype and C-allele elevated the PDAC risk by 4.91 and 3.49-fold, respectively, with no relationship to disease severity. The rs13384548 polymorphism showed no significant association with PDAC susceptibility. sCTLA-4 correlated positively with CA19-9 and CEA levels, with the highest levels found in individuals possessing the rs231726 TT genotype and high malignancy grades. These findings highlight the potential of CTLA-4 SNPs and sCTLA-4 as biomarkers for PDAC diagnosis and prognosis. Integrating these biomarkers into screening programs can offer improved strategies for early detection and disease management in high-risk populations. © 2025 The Authors.


Keywords

CTLA-4; Gene polymorphisms; Immune checkpoint; Pancreatic ductal adenocarcinoma; rs11571317; rs231726; CA 19-9 antigen; carcinoembryonic antigen; cytotoxic T lymphocyte antigen 4; adult; allele; antigen blood level; Article; cancer diagnosis; cancer grading; cancer growth; cancer patient; cancer prognosis; cancer risk; cancer screening; cancer susceptibility; cancer therapy; case control study; cohort analysis; controlled study; CTLA 4 gene; disease severity; early diagnosis; Egyptian; female; gene function; genetic association; genetic risk; genetic variability; genotype; high risk patient; human; major clinical study; male; middle aged; pancreatic ductal carcinoma; patient care; risk assessment; single nucleotide polymorphism


Citation Information

Scopus Citations: 2


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region